25th week of 2019 patent applcation highlights part 9 |
Patent application number | Title | Published |
20190183831 | METHODS OF TREATING MIXED DYSLIPIDEMIA - The present disclosure relates to, inter alia, methods of treating cardiovascular-related disease. | 2019-06-20 |
20190183832 | NUTRITIONAL BOLUS FOR ANIMALS - Formulations and methods for reducing or preventing stress-related weight loss in animals have been developed. The formulations include medium-chain triglyceride (MCT) oil as the active agent. The methods include subcutaneously administering the formulation to an animal in need thereof shortly before, during, or after the stress. The stress may be due to restraint, surgery, injury, transportation, relocation, birth, separation, exercise, training, handling, rescue or other action that elicits stress or high energy expenditure or involves an animal with low energy reserves, such as a newborn or sick animal. The animals are typically agriculture animals, laboratory animals, veterinary animals, zoo animals, or pets. Also provided are kits containing ready-to-use dosage forms for reducing or preventing stress-related weight loss in animals. | 2019-06-20 |
20190183833 | Compounds For The Treatment Of Neuromuscular Disorders - The present invention relates to compounds suitable for treating, ameliorating and/or preventing neuromuscular disorders, including the reversal of drug-induced neuromuscular blockade. The compounds as defined herein preferably inhibit the CIC-1 ion channel. | 2019-06-20 |
20190183834 | Compounds For The Treatment Of Neuromuscular Disorders - The present invention relates to compounds suitable for treating, ameliorating and/or preventing neuromuscular disorders, including the reversal of drug-induced neuromuscular blockade. The compounds as defined herein preferably inhibit the CIC-1 ion channel. | 2019-06-20 |
20190183835 | PHARMACEUTICAL FORMULATIONS COMPRISING 9-CIS-RETINYL ESTERS IN A LIPID VEHICLE - Pharmaceutical formulations comprising 9-cis-retinyl esters in a lipid vehicle are described as retinoid replacement therapies for treating retinal degenerations in humans. | 2019-06-20 |
20190183836 | MODIFIED RELEASE GAMMA- HYDROXYBUTYRATE FORMULATIONS HAVING IMPROVED PHARMACOKINETICS - Modified release formulations of gamma-hydroxybutyrate having improved dissolution and pharmacokinetic properties are provided, and therapeutic uses thereof. | 2019-06-20 |
20190183837 | COMPOSITIONS AND METHODS OF USE OF PHORBOLESTERS - Methods and compositions containing a phorbol ester or a derivative of a phorbol ester are provided for the treatment of chronic and acute conditions. Such conditions may be caused by disease, be symptoms or sequelae of disease. Chronic and acute conditions may be due to viral infections such as HIV and AIDS, neoplastic diseases stroke, kidney disease, urinary incontinence, autoimmune disorders, Parkinson's disease, prostate hypertrophy, aging, or the treatment of such diseases. Additional compositions and methods are provided which employ a phorbol ester or derivative compound in combination with at least one additional agent to yield more effective treatment tools against acute and chronic conditions in mammalian subjects. | 2019-06-20 |
20190183838 | COMPOSITIONS COMPRISING A FATTY ACID OIL MIXTURE AND A FREE FATTY ACID, AND METHODS AND USES THEREOF - Compositions comprising a fatty acid oil mixture and at least one free fatty acid, and uses thereof are disclosed. Further disclosed are preconcentrates capable of forming a self- nanoemulsifying drug delivery system (SNEDDS), a self-microemulsifying drug delivery system (SMEDDS) or self-emulsifying drug delivery systems (SEDDS) in an aqueous solution. Preferred fatty acids are eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) in a form chosen from ethyl ester and triglyceride. | 2019-06-20 |
20190183839 | METHODS OF TREATING PEDIATRIC METABOLIC SYNDROME - In various embodiments, the present invention provides methods of treating and/or preventing pediatric metabolic syndrome comprising administering to a subject in need thereof a pharmaceutical composition comprising eicosapentaenoic acid or a derivative thereof. | 2019-06-20 |
20190183840 | COMPOSITIONS AND METHODS FOR REDUCING A FATTY ACID DESATURATION INDEX IN A SUBJECT IN NEED THEREOF - In various embodiments, the present invention provides compositions and methods for treating and/or preventing cardiovascular-related diseases in subject in need thereof. | 2019-06-20 |
20190183841 | NUTRITIONAL SUPPLEMENT AND PROCESS OF PREPARATION - Processes for producing a nutritional supplement that contains sulforaphane, and supplements formed thereby. Such a process includes combining a cruciferous vegetable, for example, broccoli sprouts, with strains of | 2019-06-20 |
20190183842 | Entacapone-related Compounds to Treat Macular Degeneration - The invention provides use of entacapone, an entacapone derivative or a stereoisomer, hydride, or pharmaceutically-acceptable salt thereof, in a person in need thereof, to treat or inhibit macular degeneration or age-related macular degeneration, and related compostions. | 2019-06-20 |
20190183843 | USE OF DIANHYDROGALACTITOL OR DERIVATIVES OR ANALOGS THEREOF FOR TREATMENT OF PEDIATRIC CENTRAL NERVOUS SYSTEM MALIGNANCIES - The use of dianhydrogalactitol provides a novel therapeutic modality for the treatment of malignancies of the central nervous system in pediatric patients, including glioblastoma multiforme (GBM) high grade glioma, and medulloblastoma. Dianhydrogalactitol acts as an alkylating agent on DNA that creates N | 2019-06-20 |
20190183844 | METHODS FOR TREATING GAUCHER DISEASE - Methods for treating Gaucher disease in patients with renal or hepatic impairment. | 2019-06-20 |
20190183845 | Cream and Oil for Facial Rejuvenation - A mixture and method of production of a topical formulation for facial rejuvenation using | 2019-06-20 |
20190183846 | METHODS FOR THE TREATMENT OF MAST CELL RELATED DISORDERS WITH MAST CELL STABILIZERS - Methods for the treatment of systemic mast cell related disorders treatable with mast cell stabilizers, including mast cell related disorders, are provided. | 2019-06-20 |
20190183847 | METHODS FOR THE TREATMENT OF SYSTEMIC DISORDERS TREATABLE WITH MAST CELL STABILIZERS, INCLUDING MAST CELL RELATED DISORDERS - Methods for the treatment of systemic disorders treatable with mast cell stabilizers, including mast cell related disorders, are provided. | 2019-06-20 |
20190183848 | LIQUID CARBON DIOXIDE BOTANICAL EXTRACTION SYSTEM - A process is disclosed for extracting cannabinoids from plant materials. The process comprises providing a pressurizable extraction vessel having a rotatable drum with baffles, along with providing a solvent permeable filter bag. The plant material is placed within the filter bag, and the filter bag containing the plant material is placed within the extraction vessel. The extraction vessel is then filled with subcritical liquid carbon dioxide and rotated to so that the plant material is in contact with the liquid carbon dioxide. After a selected period of time, the liquid carbon dioxide solvent containing the cannabinoid extracted from the plant material is removed from the vessel, and sent to a separator. The separator separates the cannabinoid from the liquid carbon dioxide solvent. | 2019-06-20 |
20190183849 | COMPOUND AND METHOD FOR TREATMENT OF DISEASES AND DISORDERS - The disclosed invention generally relates to treatment and/or prevention of symptoms associated with cannabinoid responsive diseases and disorders in subjects in need thereof, as well as the method of administering therapeutically-effective amount of a pharmaceutical compound containing cannabinoids. The disclosed invention further relates to pharmaceutical compounds for treating and/or preventing symptoms associated with said diseases and disorders. | 2019-06-20 |
20190183850 | NEW CANNABIS TABLET FORMULATIONS AND COMPOSITIONS AND METHODS OF MAKING THE SAME - Disclosed herein are compositions comprising an oil having at least one cannabinoid and at least one solid powder and methods of making and using the same. In one embodiment, the compositions disclosed herein are suitable for making cannabinoid containing tablets by pressing a composition of this disclosure with one or more formulating agents, such as binders, fillers, bulking agents, excipients, etc. | 2019-06-20 |
20190183851 | USE OF 3,4,7-TRIHYDROXYISOFLAVONE OR 3-METHOXYDAIDZEIN IN PREPARATION OF DRUG FOR INHIBITING PLATELET AGGREGATION AND THROMBOSIS - A use of 3,4,7-trihydroxyisoflavone or 3-methoxydaidzein is provided for implementation in preparation of a drug for inhibiting platelet aggregation. The 3,4,7-trihydroxyisoflavone or 3-methoxydaidzein has a significant inhibition effect on platelet aggregation, and bleeding test conducted with these embodiments show that all of the mice administrated with 3,4,7-trihydroxyisoflavone and 3-methoxydaidzein did not show any significant hemorrhagic activity, while the control group, i.e., the group administrated with the same concentration of clopidogrel showed very significant hemorrhagic activity. Thus, the use of such a drug of the present invention is useful in inhibiting platelet aggregation, and the use of such a drug can reduce the risk of bleeding, is safe for use, and expands the clinical and medical applications thereof. | 2019-06-20 |
20190183852 | METHOD FOR PRODUCING NOBILETIN-CONTAINING SOLID DISPERSION - A nobiletin composition having high water solubility and a method for easily producing the same are provided. A method for producing a solid dispersion comprising nobiletin, comprising the step of mixing nobiletin or a nobiletin-containing product with a water-soluble hesperidin derivative, and then melting the mixture by heating; and the step of solidifying the melted product by cooling. A nobiletin-containing composition produced by the method. | 2019-06-20 |
20190183853 | WATER SOLUBLE COMPOSITIONS COMPRISING PURIFIED CANNABINOIDS - This disclosures relates to new compositions and methods for making cannabinoid formulations. In one embodiment, this disclosure provides water soluble compositions comprising a first purified cannabinoid and Vitamin E TPGS. In one embodiment, the disclosure herein comprises a method of making powders comprising heatings material to a first temperature and a second temperature. | 2019-06-20 |
20190183854 | COMPOSITIONS AND METHODS FOR PREVENTING AND TREATING CONDITIONS - Provided herein are compositions comprising a stable water-in-silicone emulsion, and methods and kits comprising the compositions for treating conditions. | 2019-06-20 |
20190183855 | COMPOSITION FOR TREATING HEPATITIS B, AND METHOD FOR EVALUATING REPLICATION ACTIVITY OF HEPATITIS B VIRUS - An evaluation system for replication activity of HBV capable of visualizing and quantifying replication of HBV DNA in a short period of time inexpensively, safely, and rapidly and a method for evaluation using the system are developed and provided. Moreover, a novel composition for inhibiting HBV replication with a mode of action different from that of conventional anti-HBV drugs is developed and provided. A therapeutic agent for hepatitis B comprising as an active ingredient an HBV-Pol activity inhibitor consisting of a phosphorylation inhibitor that inhibits phosphorylation of a TxY motif present in Terminal protein region of HBV-Pol is provided. | 2019-06-20 |
20190183856 | METHODS FOR TREATING CANCER - One embodiment relates to a method of treating cancer by administering a compound of Formula I to a patient. Another embodiment relates to a method of treating a patient having cancer associated p53 mutation that includes administering to a patient the compound represented by the Formula I: | 2019-06-20 |
20190183857 | METHODS FOR IDENTIFYING AND USING INHIBITORS OF CASEIN KINASE 1 EPSILON ISOFORM FOR INHIBITING THE GROWTH AND/OR PROLIFERATION OF MYC-DRIVEN TUMOR CELLS - In one aspect, the invention provides a method for inhibiting the growth and/or proliferation of a myc-driven tumor cell comprising the step of contacting the tumor cells with a CSNK1ε inhibitor. In another aspect, the invention provides a method of treating a subject suffering from a tumor comprising myc-driven tumor cells, comprising administering to the subject an amount of a composition comprising a CSNK1ε inhibitor effective to inhibit the growth and/or proliferation of the tumor cells. | 2019-06-20 |
20190183858 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING LDL CHOLESTEROL-RELATED DISEASES, CONTAINING RIBOSOME-BINDING PREPARATION - The present invention relates to: a pharmaceutical composition for preventing or treating LDL cholesterol-related diseases, containing a ribosome-binding preparation; a food composition; and a method for preventing or treating LDL cholesterol-related diseases by using the composition. According to the present invention, the ribosome-binding preparation selectively increases the expression of an LDL receptor in intestinal epithelial cells so as to promote LDL absorption in blood and tissue, such that LDL level in the blood can be reduced, thereby being useful for preventing or treating various LDL cholesterol-related diseases including LDL hypercholesterolemia, hyperlipidemia, hypertension and apoplexy. | 2019-06-20 |
20190183859 | AQUEOUS-BASED METRONIDAZOLE GEL FORMULATIONS - The present disclosure provides mucoadhesive aqueous-based gel formulations of metronidazole useful for a variety of purposes including intravaginal application as a therapeutic approach towards the treatment of individuals suffering from and/or diagnosed with bacterial vaginosis. | 2019-06-20 |
20190183860 | METHOD FOR THE TREATMENT OF ATG4-RELATED DISORDERS - The present invention relates to the area of ATG4-related disorders. More particularly, the present invention relates to a method of treating an ATG4B-related disorder comprising a step of administering a subject with an effective amount of tioconazole. The present invention relates also to a method of increasing a subject's responsiveness to a therapy for a cancer comprising inhibition of ATG4B activity in cells; said method comprises administering the subject with an effective amount of tioconazole. The present invention also relates to a method for enhancing or inducing a response in a cancer cell consisting of cytotoxicity, chemosensitivity or starvation-sensitivity; said method comprises administering a subject with an effective amount of tioconazole to inhibit ATG4B's activity. | 2019-06-20 |
20190183861 | COMPOSITIONS AND METHODS OF MODULATING S-NITROSYLATION - A method of treating cardiovascular disorders and diseases in a subject in need therof includes administering to the subject an ADH inhibitor, AKR inhibitor, and/or SNO-CoAR inhibitor at an amount(s) effective to promote S-nitrosylation of proteins in the subject, wherein the ADH inhibitor and/or SNO-CoAR inhibitor is not an ADH3 inhibitor. | 2019-06-20 |
20190183862 | ISOXAZOLINE PARASITICIDE FORMULATIONS AND METHODS FOR TREATING BLEPHARITIS - Disclosed herein are methods for treating or preventing ophthalmic and dermatologic conditions in a patient, including ocular surface conditions such as blepharitis. The methods can include topically administering directly to an ocular surface of one or more eyes of a patient in need of treatment thereof an effective amount of an isoxazoline parasiticide, formamidine parasiticide, or other active ingredient, formulated into an ophthalmic composition, the ophthalmic composition further comprising a pharmaceutically acceptable vehicle. Compositions are also disclosed. | 2019-06-20 |
20190183863 | Compounds For The Treatment Of Neuromuscular Disorders - The present invention relates to compounds suitable for treating, ameliorating and/or preventing neuromuscular disorders, including the reversal of drug-induced neuromuscular blockade. The compounds as defined herein preferably inhibit the CIC-1 ion channel. | 2019-06-20 |
20190183864 | OCULAR FORMULATIONS FOR DRUG-DELIVERY TO THE POSTERIOR SEGMENT OF THE EYE - The present invention relates to topical formulations comprising a compound of the following formula: | 2019-06-20 |
20190183865 | NSD FAMILY INHIBITORS AND METHODS OF TREATMENT THEREWITH - Provided herein are small molecule inhibitors of NSD1, NSD2 and/or NSD3 activity, and methods of use thereof for the treatment of disease, including leukemia, breast cancer, osteosarcoma, lung and prostate cancers and other solid tumors as well as other diseases dependent on the activity of NSD1, NSD2 and/or NSD3. | 2019-06-20 |
20190183866 | 5-SUBSTITUTED BENZIMIDAZOLE AND 5-SUBSTITUTED AZABENZIMIDAZOLE DERIVATIVE BOTH HAVING AMPK ACTIVATION EFFECT - Provided is a compound which is useful as an AMPK activator, represented by formula: | 2019-06-20 |
20190183867 | NOVEL QUINUCLIDINE DERIVATIVES AND MEDICINAL COMPOSITIONS CONTAINING THE SAME - Provided is a method for treating chronic obstructive pulmonary disease or chronic bronchitis, or inhibiting bronchospasm, which method comprises use of a powder inhaler to administer to a human patient in need of such treatment an effective amount of a powder inhalant, wherein the powder inhalant comprises 3(R)-(2-hydroxy-2,2-dithien-2-ylacetoxy)-1-(3-phenoxypropy1)-1-azoniabicyclo[2.2.2]octane bromide. | 2019-06-20 |
20190183868 | FORMULATIONS AND TREATMENTS EMPLOYING HYDROXYPYRIDONATE ACTINIDE/LANTHANIDE DECORPORATION AGENTS - Provided herein are methods for treating a subject in need of such treatment comprising administering a therapeutically effective amount of one or more pharmaceutical compositions comprising a 1,2-HOPO chelating agent and/or a 3,2-HOPO chelating agent to a subject in need of such treatment. The subject can be one who has been, or will be, exposed to one or more known or unknown actinides and/or lanthanides, or a mixture thereof. | 2019-06-20 |
20190183869 | TREATMENT OF FABRY DISEASE IN ERT-NA VE AND ERT-EXPERIENCED PATIENTS - Provided are dosing regimens for the treatment of Fabry disease in a patient. Certain methods relate to the treatment of ERT-experienced or ERT-nave Fabry patients. Certain methods comprise administering to the patient about 123 mg free base equivalent of migalastat for improving left ventricular mass and/or improving podocyte globotriaosylceramide. | 2019-06-20 |
20190183870 | COMBINATION OF HISTONE DEACETYLASE INHIBITOR AND IMMUNOTHERAPY - A method of reducing cancer cell growth, a method of increasing sensitivity of cancer cells to CTL mediated killing, and a method of increasing sensitivity of cancer cells to NK mediated killing are provided. The methods comprise treating cancer cells with a combination of a HDAC inhibitor and immunotherapy. | 2019-06-20 |
20190183871 | USE OF CICLOPIROX FOR THE TREATMENT OF CONGENITAL ERYTHROPOIETIC PORPHYRIA - The present invention relates to the use of the compound ciclopirox or a pharmaceutically acceptable salt or solvate thereof for the treatment and/or prevention of congenital erythropoietic porphyria (CEP). | 2019-06-20 |
20190183872 | METHODS OF ADMINISTERING PIRFENIDONE THERAPY - The present invention relates to methods involving avoiding adverse drug interactions with fluvoxamine and pirfenidone or other moderate to strong inhibitors of CYP enzymes. | 2019-06-20 |
20190183873 | METHODS FOR THE ADMINISTRATION OF ILOPERIDONE - The present invention relates to methods for the identification of genetic polymorphisms that may be associated with a risk for QT prolongation after treatment with iloperidone and related methods of administering iloperidone to patients with such polymorphisms. | 2019-06-20 |
20190183874 | (2S)-1-[4-(3,4-DICHLOROPHENYL)PIPERIDIN-1-YL]-3-[2-(5-METHYL-1,3,4-OXADIAZ- OL-2-YL)BENZO[B]FURAN-4-YLOXY] PROPAN-2-OL OR ITS METABOLITE FOR TREATING ANXIETY DISORDERS - The present disclosure describes compositions and methods for treating at least one symptom of an anxiety disorder in a human subject. The compositions and methods employ a therapeutically effective amount of a compound of formula I (Compound I) or formula II (Compound II), or a pharmaceutically acceptable salt, hydrate or solvate of Compound I or II: | 2019-06-20 |
20190183875 | TREATING OF SIDE-EFFECTS RESULTING FROM CHEMODENERVATION - The present disclosure relates generally to methods of restoring neuromuscular transmission by locally administering an effective dose of a composition comprising an anticholinesterase to a non-responsive muscle. The disclosure also relates to methods of reversing a neurotoxin-induced muscle paralysis or muscle weakness, the method comprising locally administering a composition comprising an anticholinesterase to the patient. | 2019-06-20 |
20190183876 | ATROPINE PHARMACEUTICAL COMPOSITIONS - The inventive subject matter is directed to compositions and methods for sterile and storage stable low-dose atropine formulations with improved stability. Most preferably, the compositions presented herein are substantially preservative free and exhibit less than 0.35% tropic acid from degradation of atropine. Advantageously, contemplated formulations are also substantially free of preservatives. | 2019-06-20 |
20190183877 | COMPLEXES OF IVACAFTOR AND ITS SALTS AND DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM - Disclosed herein are pharmaceutically acceptable complex formulations comprising complexes of Ivacaftor, or a salt or derivative thereof, together with complexation agents and pharmaceutically acceptable excipients; processes for the preparation thereof; and pharmaceutical compositions containing them. The complexes possess instantaneous redispersibility, increased apparent solubility and permeability compared to KALYDECO, no observable food effect which deliver the opportunity of precise dosing and ease of administration of the reconstituted complex Ivacaftor in solution form. | 2019-06-20 |
20190183878 | COMBINATION TREATMENT OF OCULAR INFLAMMATORY DISORDERS AND DISEASES - The present disclosure provides a combination of a fused bicyclic amine compound and an anti-inflammatory agent for treating ocular inflammatory disorders and diseases. Further provided are pharmaceutical compositions of the compound and the anti-inflammatory agent. | 2019-06-20 |
20190183879 | Crenolanib for Treating FLT3 Mutated Proliferative Disorders - The present invention relates to the use of crenolanib, in a pharmaceutically acceptable salt form for the treatment of FLT3 mutated proliferative disorders driven by constitutively activated mutant FLT3, and to a method of treatment of warm-blooded animals, preferably humans, in which a therapeutically effective dose of crenolanib is administered to an animal suffering from said disease or condition: | 2019-06-20 |
20190183880 | METHOD OF INHIBITING MUTANT C-KIT - The present invention includes a method of reducing or inhibiting the kinase activity of C-KIT mutant tyrosine kinase activity in a cell or a subject, and the use of such compound for treating mutant C-KIT driven cell proliferative disorder(s) in a subject related to using a compound of the present invention: | 2019-06-20 |
20190183881 | USE OF CDK8 INHIBITORS TO TREAT DISEASES OF INFLAMMATION AND AUTOIMMUNITY - A method for treating inflammation and/or autoimmune diseases comprises administering to a subject in need thereof, a composition comprising a CDK8 inhibitor. In another aspect, a method for increasing IL-10 production comprises administering to a subject in need thereof a CDK8 inhibitor. In another aspect, a method for enhancing T | 2019-06-20 |
20190183882 | PULMONARY HYPERTENSION PREVENTATIVE OR THERAPEUTIC AGENT CONTAINING COMPONENT EXHIBITING SELENOPROTEIN P ACTIVITY-INHIBITING EFFECT - A problem to be solved by the present invention is to provide a novel preventive or therapeutic agent for pulmonary hypertension containing as an active ingredient a compound that has not been known for a therapeutic effect on pulmonary hypertension heretofore. The present invention provides a preventive or therapeutic agent for pulmonary hypertension containing an ingredient having a selenoprotein P activity-inhibiting action. | 2019-06-20 |
20190183883 | Sustained Release Formulation Of Naltrexone - A sustained-release oral dosage form of naltrexone or a pharmaceutically acceptable salt thereof is provided. The oral dosage form may be administered with another compound. Administration of the oral dosage form may reduce a side effect, which may be a side effect at least partially attributable to a weight-loss treatment. The oral dosage form may be administered to treat a weight-loss condition. | 2019-06-20 |
20190183885 | COMPOSITIONS AND METHODS THEREOF - Compounds of Formula I: | 2019-06-20 |
20190183886 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS - Provided herein are compounds of the Formula I: | 2019-06-20 |
20190183887 | VOLATILE METABOLITE PROFILES FOR THE DIAGNOSIS AND TREATMENT OF MUCORALES FUNGI - Methods for diagnosing, treating, and monitoring the treatment of mucormycosis are described. The methods can include detecting the presence of one or more volatile organic compounds (VOCs) in the breath of subjects suspected of having mucormycosis. | 2019-06-20 |
20190183888 | METHODS AND COMPOSITIONS FOR SLEEP DISORDERS AND OTHER DISORDERS - Use of particular substituted heterocycle fused gamma-carboline compounds as pharmaceuticals and pharmaceutical compositions comprising them for the treatment of one or more disorders involving the 5-HT2A, SERT and/or dopamine D2 pathways are disclosed. In addition, the compounds may be combined with other therapeutic agents for the treatment of one or more sleep disorders, depression, psychosis, dyskinesias, and/or Parkinson's disease or any combinations. | 2019-06-20 |
20190183889 | PLASMODIAL SURFACE ANION CHANNEL INHIBITORS FOR THE TREATMENT OR PREVENTION OF MALARIA - The invention provides methods of treating or preventing malaria comprising administering to an animal an effective amount of a compound of formula I: | 2019-06-20 |
20190183890 | METHODS AND COMPOSITIONS FOR PROMOTING HAIR GROWTH - Disclosed are methods and compositions for treating alopecia in a subject. The methods and compositions include hydralazine in a pharmaceutically acceptable preparation for topical administration. Also disclosed are combinations of hydralazine and a type II 5α-reductase, an anti-inflammatory agent, or a vasoconstrictor. | 2019-06-20 |
20190183891 | VORICONAZOLE INCLUSION COMPLEXES - Described are voriconazole formulations including 2-hydroxypropyl-β-cyclodextrins and the preparation thereof. | 2019-06-20 |
20190183892 | COMBINED PHARMACEUTICAL COMPOSITION - The present invention relates to a physicochemically stable pharmaceutical composition, in a unit dose characterized in that it comprises effective amounts of the active ingredients thiamine (Vitamin B1), pyridoxine (Vitamin B6), a flavonoid such as quercetin and a polyphenol such as curcumin, or their pharmaceutically acceptable salts in combination with pharmaceutically acceptable excipients, for the prevention of the formation and/or trapping of advanced glycation end products (glyoxal, methylglyoxal, N-carboxymethyl-lysine, N-carboxyethyl-lysine, pyrraline, pentosidine, lysine dimer, etc.), which can be used in the treatment and/or prevention of complications of diabetes mellitus (diabetic neuropathy, nephropathy and retinopathy). | 2019-06-20 |
20190183893 | Low dose of sildenafil as an antitumor drug - The present invention is related to the medical technology field. This invention discloses the application of sildenafil at low doses as an antitumor drug, with the chemical name of 1-[4-ethyl-3-[5-(6,7-Two-methyl-7-oxygen generation-3-propyl H pyrazole and [4,3d] pyrimidine)] phenyl sulfonyl-4-biphenyl methyl piperazine, and the use dosage is: the oral dosage of 0.04˜0.5 mg per 1 kg of body weight, or 2˜25 mg for an adult with body weight of 50 kg, or injection dosage of 0.04˜0.2 mg per 1 kg of body weight, or 2˜10 mg for an adult with body weight of 50 kg, or external dosage in a mass percentage of less than 1% of sildenafil. This invention is applicable to the treatment of malignant tumors. It inhibits tumor growth by more than 50% without significant toxic or side effects, and thereby, sildenafil can be used in control of tumor growth and for improvement of other treatments of tumor. | 2019-06-20 |
20190183894 | METHOD OF TREATMENT OF DIABETIC FOOT ULCERS - A novel method of treating, preventing and maintaining of diabetic foot ulcers is described. | 2019-06-20 |
20190183895 | IMIPRIDONES FOR GLIOMAS - Imipridones selectively modulate Class A G protein-coupled receptors (GPCRs), such as the D2-like subfamily of dopamine receptors, and are useful for treating conditions and disorders in need of such modulation, such as cancers. Specifically, the cancer is a midline glioma, a cancer having a histone H3 mutation, or both. In addition, methods of identifying whether a subject having these conditions, is likely to be responsive to a treatment regimen, such as imipridone administration, are provided. Furthermore, methods of assessing the effectiveness of a treatment regimen, such as imipridone administration, monitoring, or providing a prognosis for a subject with these condition are also provided. | 2019-06-20 |
20190183896 | ONE STEP MILLING PROCESS FOR PREPARING MICRONIZED PALIPERIDONE ESTERS - Pharmaceutical compositions comprising at least one wetting agent, at least one excipient, at least one buffer, at least one pH modifier, and at least one active pharmaceutical ingredient. Methods for preparing the pharmaceutical compositions in which the active pharmaceutical ingredient is milled to provide a particle size distribution using a one-step milling process. | 2019-06-20 |
20190183897 | ANTITUMOR DRUG FOR INTERMITTENT ADMINISTRATION OF FGFR INHIBITOR - The problems to be solved by the present invention are to provide a novel FGFR inhibitor that is potent and highly selective, and to provide an antitumor agent with which side effects such as an elevated blood phosphorus concentration are alleviated while maintaining the antitumor effect of the FGFR inhibitor. The present invention provides an antitumor agent comprising a 3,5-di-substituted benzene alkynyl compound represented by general formula (I) or salt thereof, which is used by administering the 3,5-di-substituted benzene alkynyl compound or salt thereof according to an administration schedule of two or more times/week at an administration interval of at least one day between doses. | 2019-06-20 |
20190183898 | COMBINATION THERAPY TO IMPROVE BRAIN FUNCTION OR PROMOTE NEUROGENESIS FOR TREATING NEURODEGENERATIVE CONDITIONS - Disclosed herein are methods and materials for improving brain function and/or promoting neurogenesis m a patient suffering from impaired brain function. Specifically exemplified herein ls the co-administration of phenserine and NBI-18. A method of treating a neurodegenerative disease in a patient in need thereof, said method comprising co-administering to the patient phenserine, or pharmaceutically acceptable salt thereof, and NBI-18, or pharmaceutically acceptable salt thereof, in respective amounts and frequency such that they work together to improve brain function or induce neurogenesis in the patient. | 2019-06-20 |
20190183899 | PYRROLOPYRIMIDINE COMPRISING CYCLOPENTYL SUBSTITUENT - A pyrrolopyrimidine comprising a cyclopentyi substituent. The present invention specifically relates to a compound represented by formula. A and a stereoisomer and pharmaceutically acceptable salt thereof. The invention further relates to a method for manufacturing the pyrrolopyrimidine comprising the cyclopentyl substituent represented by formula A, a pharmaceutical composition, and an application of the compound in treating a disease induced by Janus kinase. | 2019-06-20 |
20190183900 | COMPOSITION FOR PROLIFERATION, DIFFERENTIATION PROMOTION, OR SENESCENCE INHIBITION OF STEM CELLS, CONTAINING JAK1 INHIBITOR AS ACTIVE INGREDIENT - Disclosed is a composition for proliferation, differentiation promotion, and senescence inhibition of stem cells, including a JAK1 inhibitor as an active ingredient, wherein JAK1 inhibitor-treated stem cells or JAK1 knockout stem cells have an activity for decreasing senescence and increasing the survival rate of the stem cells, thereby being usable in a composition for proliferation, differentiation promotion, and senescence inhibition of stem cells. | 2019-06-20 |
20190183901 | COMBINATIONS AND USES AND TREATMENTS THEREOF - Methods for treating HIV in a human using combinations of: bictegravir and one of two different maturation inhibitors are disclosed, as well as compositions containing such compounds are provided. | 2019-06-20 |
20190183902 | Apilimod Compositions and Methods for Using Same - The present invention relates to methods for treating cancer with apilimod and related compositions and methods. | 2019-06-20 |
20190183903 | TROPOMYOSIN-RELATED KINASE (TRK) INHIBITORS - Tropomyosin-related kinase inhibitors (Trk inhibitors) are small molecule compounds useful in the treatment of disease. Trk inhibitors can be used as pharmaceutical agents and in pharmaceutical compositions. Trk inhibitors are useful in the treatment of inflammatory diseases, autoimmune disease, defects of bone metabolism and/or cancer, and are particularly useful in the treatment of osteoarthritis (OA), pain, and pain associated with OA. Trk inhibitors are also useful for inhibiting tropomyosin-related kinase A (TrkA), tropomyosin-related kinase B (TrkB), tropomyosin-related kinase C (TrkC), and/or c-FMS (the cellular receptor for colony stimulating factor-1 (CSF-1)). | 2019-06-20 |
20190183904 | Methods for Diagnosing and Managing Treatment of Atopic Dermatitis - Provided herein is a method of diagnosing and treating a subject suffering from atopic dermatitis (AD), the method comprising: (a) obtaining a skin biopsy from a subject suspected of suffering from AD; (b) determining a level of RNA expression in the skin biopsy of genes selected from the 89ADGES gene panel; (c) comparing the determined level of RNA expression of the selected genes to the level of RNA expression of the selected genes in a reference sample comprising RNA expression products from normal healthy skin cells; (d) diagnosing the subject as suffering from AD when specific genes are up-regulated compared to the reference sample and when specific genes are down-regulated compared to the reference sample; and (e) treating the subject with a therapy effective for the treatment of AD. Methods of managing treatment of a subject suffering from AD are also provided. | 2019-06-20 |
20190183905 | PHEROMONE COMPOSITIONS FOR STIMULATING EARLY ONSET OF ESTRUS AND REDUCING LABOR NEEDS IN BREEDING PERI-PUBERTAL SUIDS AND METHODS OF USE - The present disclosure provides for pheromonal compositions and methods of using the compositions for stimulating early onset of estrus in a peri-pubertal suid and methods of improving performance of the peri-pubertal female suid. The composition may comprise at least one steroid hormone and a heterocyclic aromatic compound. The method comprises administering the pheromone composition to the suid for a period of time. | 2019-06-20 |
20190183906 | COMPRESSED CAPSULES FOR GIVING BIRTH TO MALES - The present invention is related to baby love male capsules including active ingredients such as fludrocortisone, bumetanide, sodium bicarbonates, sodium chloride, and Licourice extract, inactive ingredients such as gelatin, plasticizers, moisture absorbents, and preservatives. | 2019-06-20 |
20190183907 | COMPOSITIONS COMPRISING DEXAMETHASONE - A pharmaceutical composition useful for the treatment of multiple myeloma in combination with an anti-cancer drug is provided. The pharmaceutical composition includes high-dose dexamethasone or a pharmaceutically acceptable salt or solvate thereof. | 2019-06-20 |
20190183908 | AUTOPHAGY ACTIVATORS FOR TREATING OR PREVENTING SKIN INJURY - An autophagy activator, such as vitamin D, for use in a method of treating or preventing skin damage in a subject in need thereof is described, that includes administering to the subject a therapeutically effective amount of said activator. The method can include administering doses of the autophagy activator that are substantially higher than those typically used. Also disclosed are a method of monitoring the immunomodulatory effects of an autophagy activator on skin damage in a subject, and a method of correlating the dosage of oral administration of cholecalciferol in humans with the dosage of an intraperitoneal injection of 25(OH)D in mice. | 2019-06-20 |
20190183909 | METHODS AND MATERIALS FOR TREATING CALCIFIC AORTIC VALVE STENOSIS - This document provides methods and materials involved in treating cardiovascular conditions such as calcific aortic valve stenosis. For example, methods and materials for using sGC agonists or a combination of sGC agonists and PDE5A inhibitors to reduce calcification of heart valves and/or vessels or to slow progression of aortic sclerosis to calcific aortic valve stenosis are provided. | 2019-06-20 |
20190183910 | ENHANCING DNA REPAIR AND PREVENTING AGING AND ITS CONSEQUENCES IN REPRODUCTIVE AND OTHER CELLS - Embodiments of the present invention generally relate to methods for improving male fertility, and in particular for using sphingosine 1 phosphate (S1P) for improving the quality and/or longevity of sperm. | 2019-06-20 |
20190183911 | EFFERVESCENT FORMULATION BASED ON PYRIDOXAL-5-PHOSPHATE - Provided is a fast-dissolving effervescent pharmaceutical formulation of pyridoxal-5-phosphate, and to the use thereof in the treatment of neonatal epilepsy and also of metabolic disorders with a need for pyridoxal-5-phosphate. | 2019-06-20 |
20190183912 | ANTIVIRAL PRODRUGS OF TENOFOVIR - Compounds of Formula I: and pharmaceutically acceptable salts and co-crystals thereof are useful for the inhibition of HIV reverse transcriptase. The compounds may also be useful for the prophylaxis or treatment of infection by HIV and in the prophylaxis, delay in the onset or progression, and treatment of AIDS. The compounds and their salts can be employed as ingredients in pharmaceutical compositions, optionally in combination with other antiviral agents, immunomodulators, antibiotics or vaccines. | 2019-06-20 |
20190183913 | Silanol Based Therapeutic Payloads - Described herein in part are silanol based therapeutic payloads comprising a silanol terminus, a divalent spacer moiety, and a drug moiety capable of effecting a target cell or tissue. | 2019-06-20 |
20190183914 | COMPOSITIONS AND METHODS OF POTENTIATING ANTIMICROBIALS - Disclosed herein are pharmaceutical compositions comprising at least one anti-bacterial and at least one cannabinoid and methods of use in treating or preventing bacterial infection or biofilm in a subject in need thereof. | 2019-06-20 |
20190183915 | USE OF AMINOGLYCOSIDE ANALOGS IN THE TREATMENT OF RETT SYNDROME - Compounds, methods and uses of pseudo-trisaccharide aminoglycosides represented by the general formula I: | 2019-06-20 |
20190183916 | PRODUCT AND METHOD FOR INCREASING URIDINE CONCENTRATION IN BLOOD PLASMA - The invention pertains to the use of soluble sodium in the manufacture of a composition or kit of parts for (therapeutically) improving and prolonging blood plasma uridine levels and tissue availability of uridine, and/or for treating or preventing impaired blood plasma uridine levels and tissue availability of uridine, and/or for preventing/treating disorders associated with impaired blood plasma and tissue availability of uridine, in a mammal, preferably a human being, by orally co-administering soluble sodium and uridine in a molar ratio of soluble sodium to uridine of more than 1:1, preferably more than 1.5:1, more preferably more than 2:1, even more preferably at least 2.5:1, even more preferably at least 2.8:1, more preferably 3:1-15:1, most preferably 3:1-10:1, particularly 3:1-5:1. | 2019-06-20 |
20190183917 | 3'3' CYCLIC DINUCLEOTIDES WITH PHOSPHONATE BOND ACTIVATING THE STING ADAPTOR PROTEIN - Provided herein are the 3′3′ cyclic phosphonate dinucleotides of general formula J, their pharmaceutically acceptable salts, a pharmaceutical composition containing them and combinations of said substances and other medicaments or pharmaceuticals. The disclosure also relates to the use of said compounds for the treatment or prevention of diseases or conditions modifiable by STING protein modulation, such as cancer or viral, allergic and inflammatory diseases. In addition, these substances can be used as adjuvants in vaccines. | 2019-06-20 |
20190183918 | SYSTEMIC IN VIVO DELIVERY OF OLIGONUCLEOTIDES - This invention provides a method for the systemic in vivo delivery of oligonucleotides. The invention utilizes the presence of one or plurality of HES linked to an oligonucleotide to deliver a nucleic acid sequence of interest into the cytoplasm of cells and tissues of live organisms. The delivery vehicle is nontoxic to cells and organisms. Since delivery is sequence-independent and crosses membranes in a receptor-independent manner, the delivered oligonucleotide can target complementary sequences in the cytoplasm as well as in the nucleus of live cells. Sequences of bacterial or viral origin can also be targeted. The method can be used for delivery of genes coding for expression of specific proteins, antisense oligonucleotides, siRNAs, shRNAs, Dicer substrates, miRNAs, anti-miRNAs or any nucleic acid sequence in a living organism. The latter include mammals, plants, and microorganisms such as bacteria, protozoa, and viruses. | 2019-06-20 |
20190183919 | COMPOSITIONS AND METHODS FOR TREATING AND PREVENTING END STAGE RENAL DISEASE - The invention provides methods for preventing end stage renal disease (ESRD) in subjects having a disorder associated with chronic kidney failure, such as diabetes or high blood pressure. Also included are markers (miRNAs) that may be used to identify subjects who are at risk of developing ESRD. | 2019-06-20 |
20190183920 | Treatment of Arthritis and Other Musculoskeletal Disorders With Crosslinked Hyaluronic Acid - A method of treating a subject having a musculoskeletal disorder includes administering to a subject's articular site in need thereof an effective amount of a hyaluronic acid (HA) composition. In one embodiment, the HA composition includes an HA derivative, wherein carboxyl functionalities of the hyaluronic acid derivative are each independently derivatized to include an N-acylurea or O-acyl isourea, or both N-acylurea and O-acyl isourea. In another embodiment, the HA composition includes a crosslinked HA gel that is prepared by reacting an uncrosslinked HA with a biscarbodiimide in the presence of pH buffer in a range of between about 4 and about 8. The composite can optionally include at least one second bioactive agent other than the HA derivative, such as a steroid. | 2019-06-20 |
20190183921 | Compositions and Methods to Affect Skin Irritation - Compositions are described that contain treated chitosan, modified chitosan and/or modified and treated chitosan for use in formulations for skin, hair and nails, and in compositions and methods of reducing topical agent-induced skin irritation and inflammation. | 2019-06-20 |
20190183922 | NOVEL ACTIVE IMMUNOMODULATORY AGENT AND COMPOSITION CONTAINING SAME - Disclosed is a sulphated polysaccharide extracted from a red alga of the | 2019-06-20 |
20190183923 | MODULATED GUANIDINE-CONTAINING POLYMERS OR NANOPARTICLES - A modulated guanidine substituted polymer or nanoparticle has a guanidine moiety or on a plurality of repeating units of a polymer or on the surface of a nanoparticle where the guanidine moiety is modulated as a substituted amidinourea or amidinocarbamate or salt thereof. The modulated guanidine substituted polymer or nanoparticle can be prepared by direct amination of a N-Boc protected guanidine substituted conjugated polymer or N-Boc protected guanidine substituted nanoparticle, where an amine or alcohol is combined in solution or suspension with the protected conjugated polymer or nanoparticle and the resulting mixture is heated. The modulated guanidine substituted polymer or nanoparticle can be used in a cancer treatment formulation. | 2019-06-20 |
20190183924 | COMPOSITIONS OF NITRATES AND METHODS OF USE THEREOF - Inorganic anions nitrate and nitrite influence metabolic rate and glucose homeostasis. Infusion of nitrite iv caused an acute drop in resting energy expenditure (oxygen consumption) and nitrate, when given perorally, caused a reduction in oxygen consumption during exercise and a depression of the increase in blood glucose observed after an oral glucose tolerance test. The doses of nitrate and nitrite did not cause any detectable change in methemoglobin levels of blood. Also, nitrate and nitrite did not alter lactate levels in blood. This discovery provides useful treatments to regulate the energy expenditure and glucose homeostasis of a mammal by administration of inorganic nitrite and/or nitrate. | 2019-06-20 |
20190183925 | COMPOSITION FOR SUPPRESSING OR PREVENTING ABNORMALITY IN INTESTINAL ENVIRONMENT - This application provides a composition comprising hydrogen gas or dissolved hydrogen as an active ingredient for suppressing or preventing abnormality in the intestinal environment of a subject, wherein the abnormality is selected from the group consisting of bacterial translocation and bacterial species composition abnormality of intestinal flora. | 2019-06-20 |
20190183926 | METHODS OF USING INHALED NITRIC OXIDE GAS FOR TREATMENT OF ACUTE RESPIRATORY DISTRESS SYNDROME IN CHILDREN - The present invention provides a treatment of acute respiratory distress syndrome (ARDS) in children using dosing of nitric oxide at low concentrations, such as less than 10 ppm. | 2019-06-20 |
20190183927 | MEDICAL AND NUTRITIONAL COMPOSITIONS AND METHODS OF USE - Embodiments of the present invention are directed to improved medical saline compositions and methods of use thereof. Other embodiments of the invention concern nutritional compositions and methods that promote the health of the heart, kidneys, and vasculature in a subject at risk of developing disease. | 2019-06-20 |
20190183928 | PHARMACEUTICAL COMPOSITIONS COMPRISING CHROMIUM AND CARBOHYDRATE BLOCKERS - The present disclosure relates to pharmaceutical compositions comprising chromium, a carbohydrate blocker, and a pharmaceutically acceptable excipient; methods for supporting healthy blood sugar levels comprising administering, to a subject in need thereof, a pharmaceutical composition comprising chromium, a carbohydrate blocker, and a pharmaceutically acceptable excipient; and food or beverage additives comprising chromium and a carbohydrate blocker. | 2019-06-20 |
20190183929 | USE OF LOW DOSE ARSENIC FOR PRESERVING GENOMIC INTEGRITY - Methods and compositions are provided for inhibiting, preventing, ameliorating and/or reducing damage to DNA in non-cancerous cells in a subject undergoing chemotherapeutic treatment and/or radiation treatment of cancer cells in the subject, comprising administering to the subject one or more compounds of arsenic in a therapeutically effective amount prior to chemotherapeutic treatment and/or radiation treatment. | 2019-06-20 |
20190183930 | METHODS FOR STEM CELL TRANSPLANTATION - The present disclosure provides methods of hematopoietic stem cell transplantation (HSCT). In particular, the present disclosure provides a method of HSCT using a combination of an in-vivo T-cell depletion method, with an ex-vivo method of γδ T cell expansion and αβ T cell depletion. The in-vivo T-cell depletion method depletes (in-vivo) the alloreactive T cells that would otherwise increase the risk of GvHD. | 2019-06-20 |
20190183931 | CHIMERIC RECEPTORS TO FLT3 AND METHODS OF USE THEREOF - Antigen binding molecules, chimeric receptors, and engineered immune cells to FLT3 are disclosed in accordance with the invention. The invention further relates to vectors, compositions, and methods of treatment and/or detection using the FLT3 antigen binding molecules and engineered immune cells. | 2019-06-20 |